Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.

Autor: Hirayama AV; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Kimble EL; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Wright JH; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Fiorenza S; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Gauthier J; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA., Voutsinas JM; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Wu Q; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA., Yeung CCS; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA., Gazeau N; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Pender BS; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Kirchmeier DR; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Torkelson A; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Chutnik AN; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Cassaday RD; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Chapuis AG; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Green DJ; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Kiem HP; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Milano F; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA., Till BG; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Riddell SR; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Maloney DG; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Turtle CJ; Department of Medicine, University of Washington, Seattle, WA.; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Center, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.; Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.

Publikováno v: Blood advances [Blood Adv] 2024 Jan 23; Vol. 8 (2), pp. 453-467.

Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20 ⁺ B Cell Malignancies.

Autor: Granot N; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Rezvani AR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, Stanford University Medical Center, Stanford, California., Pender BS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Storer BE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Biostatistics, University of Washington, Seattle, Washington., Sandmaier BM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington., Storb R; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington., Maloney DG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington. Electronic address: dmaloney@fredhutch.org.

Publikováno v: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [Biol Blood Marrow Transplant] 2020 Oct; Vol. 26 (10), pp. 1811-1818. Date of Electronic Publication: 2020 Jul 18.

CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient's age, and tumor types.

Autor: Montagna, Erik¹ (AUTHOR), de Campos, Najla Santos Pacheco^2,3 (AUTHOR), Porto, Victoria Alves² (AUTHOR), da Silva, Giselle Correia Próspero² (AUTHOR), Suarez, Eloah Rabello^2,3 (AUTHOR) eloah.suarez@ufabc.edu.br

Publikováno v: BMC Cancer. 8/22/2024, Vol. 24 Issue 1, p1-16. 16p.

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

Autor: Hirayama AV; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Gauthier J; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Hay KA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of British Columbia, Vancouver, BC, Canada., Voutsinas JM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Wu Q; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Gooley T; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Li D; Juno Therapeutics, Seattle, WA; and., Cherian S; Department of Laboratory Medicine and., Chen X; Department of Laboratory Medicine and., Pender BS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Hawkins RM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Vakil A; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Steinmetz RN; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Acharya UH; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Cassaday RD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Chapuis AG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Dhawale TM; Department of Medicine, University of Washington, Seattle, WA., Hendrie PC; Department of Medicine, University of Washington, Seattle, WA., Kiem HP; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Lynch RC; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Ramos J; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Till BG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Riddell SR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Maloney DG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Turtle CJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA.

Publikováno v: Blood [Blood] 2019 Apr 25; Vol. 133 (17), pp. 1876-1887. Date of Electronic Publication: 2019 Feb 19.

Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL).

Autor: Khawaji ZY; College of Medicine, Taibah University, Madinah, Kingdom of Saudi Arabia. Zakaria.khawaji1@gmail.com., Khawaji NY; College of Medicine, Alrayan Colleges, Madinah, Kingdom of Saudi Arabia., Alahmadi MA; College of Medicine, Taibah University, Madinah, Kingdom of Saudi Arabia., Elmoneim AA; Women and Child Health Department, Taibah University, Madinah, Kingdom of Saudi Arabia.; 2nd Affiliation: Pediatric Department, Faculty of Medicine, Sohag University, Sohag, Egypt.

Publikováno v: Current treatment options in oncology [Curr Treat Options Oncol] 2024 Sep; Vol. 25 (9), pp. 1163-1183. Date of Electronic Publication: 2024 Aug 05.